A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 18 Apr 2017 Results of pooled analysis (n=185) for development of semimechanistic population PK/PD model for understanding neutropenia associated with palbociclib using patient data from NCT00141297, NCT00420056, NCT00721409 trials, published in the Journal of Clinical Pharmacology
- 12 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 according to Clinicaltrials.gov record.
- 01 Mar 2012 Results have been published in Blood.